EDAP VS IMRX Stock Comparison

PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatility

Performance

EDAP
10/100

EDAP returned -58.33% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

IMRX
10/100

IMRX returned -26.67% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

EDAP
75/100

2 analysts offer 12-month price targets for EDAP. Together, they have an average target of 0, the most optimistic target put EDAP at 0 within 12-months and the most pessimistic has EDAP at 0.

IMRX

"Analyst Price Targets" not found for IMRX

Sentiment

EDAP
70/100

EDAP had a bullish sentiment score of 69.60% across Twitter and StockTwits over the last 12 months. It had an average of 2.38 posts, 2.46 comments, and 1.77 likes per day.

IMRX

"Sentiment" not found for IMRX

Technicals

EDAP
14/100

EDAP receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

IMRX
11/100

IMRX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

EDAP
10/100

EDAP has missed earnings 9 times in the last 20 quarters.

IMRX
34/100

IMRX has missed earnings 3 times in the last 20 quarters.

Profit

EDAP
42/100

Out of the last 20 quarters, EDAP has had 11 profitable quarters and has increased their profits year over year on 4 of them.

IMRX
10/100

Out of the last 15 quarters, IMRX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

EDAP
53/100

EDAP has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

IMRX
44/100

IMRX has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

All score calculations are broken down here to help you make more informed investing decisions

EDAP TMS SA Summary

Nasdaq / EDAP
Healthcare
Medical - Devices
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.

Immuneering Corporation Class A Common Stock Summary

Nasdaq / IMRX
Healthcare
Biotechnology
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.